These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25844352)

  • 1. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer.
    Cho JS; Park MH; Ryu YJ; Yoon JH
    Ann Surg Treat Res; 2015 Apr; 88(4):187-92. PubMed ID: 25844352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of neutrophil-to-lymphocyte ratio for long-term outcomes in patients with poorly differentiated thyroid cancer.
    Oba T; Maeno K; Amitani M; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Uehara T; Ito KI
    Endocr J; 2021 Nov; 68(11):1329-1336. PubMed ID: 34219074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte Ratio Is Associated With the Proportion of Poorly Differentiated Components in Papillary Thyroid Carcinoma.
    Oba T; Maeno K; Kiyosawa N; Morikawa H; Amitani M; Chino T; Shimizu T; Ono M; Ito T; Kanai T; Uehara T; Ito KI
    J Surg Res; 2023 Jul; 287():47-54. PubMed ID: 36868123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of hematologic parameters and clinicopathological features of poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Huang D; Zhang J; Zheng X; Gao M
    Langenbecks Arch Surg; 2024 Aug; 409(1):241. PubMed ID: 39105980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation.
    Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
    Front Endocrinol (Lausanne); 2024; 15():1347362. PubMed ID: 38544687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Time Series Behavior of Neutrophil-to-Lymphocyte Ratio in Thyroid Cancer Patients on Tyrosine Kinase Inhibitor Therapy.
    Tomoda C; Sugino K; Kitagawa W; Nagahama M; Ito K
    ORL J Otorhinolaryngol Relat Spec; 2021; 83(5):347-353. PubMed ID: 33735904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.
    Fukuda N; Toda K; Fujiwara YU; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Mitani H; Takahashi S
    In Vivo; 2020; 34(5):2859-2864. PubMed ID: 32871825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
    Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
    Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.
    Romei C; Tacito A; Molinaro E; Piaggi P; Cappagli V; Pieruzzi L; Matrone A; Viola D; Agate L; Torregrossa L; Ugolini C; Basolo F; De Napoli L; Curcio M; Ciampi R; Materazzi G; Vitti P; Elisei R
    Oncol Lett; 2018 Jun; 15(6):9174-9182. PubMed ID: 29805648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMP1 acts as a potential regulator of tumor progression and dedifferentiation in papillary thyroid cancer.
    Zhou J; Xu M; Tan J; Zhou L; Dong F; Huang T
    Front Oncol; 2022; 12():1030590. PubMed ID: 36479070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in anaplastic thyroid carcinoma.
    Yamazaki H; Sugino K; Matsuzu K; Masaki C; Akaishi J; Hames K; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Masuda M; Ito K
    Endocrine; 2020 Oct; 70(1):115-122. PubMed ID: 32307657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.
    Ryder M; Ghossein RA; Ricarte-Filho JC; Knauf JA; Fagin JA
    Endocr Relat Cancer; 2008 Dec; 15(4):1069-74. PubMed ID: 18719091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing outcomes in poorly-differentiated versus anaplastic thyroid cancers treated with radiation: a surveillance, epidemiology, and end results analysis.
    Arora S; Christos P; Pham A; Desai P; Wernicke AG; Nori D; Chao KS; Parashar B
    J Cancer Res Ther; 2014; 10(3):526-30. PubMed ID: 25313732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma.
    Lee DY; Won JK; Choi HS; Park do J; Jung KC; Sung MW; Kim KH; Hah JH; Park YJ
    Thyroid; 2016 Sep; 26(9):1259-68. PubMed ID: 27412715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poorly differentiated and anaplastic thyroid cancer.
    Patel KN; Shaha AR
    Cancer Control; 2006 Apr; 13(2):119-28. PubMed ID: 16735986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.
    Giannini R; Moretti S; Ugolini C; Macerola E; Menicali E; Nucci N; Morelli S; Colella R; Mandarano M; Sidoni A; Panfili M; Basolo F; Puxeddu E
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3557-3575. PubMed ID: 30882858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
    Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dedifferentiation patterns in DTC: is PDTC an intermediate state between DTC and ATC?
    Wen D; Hu JQ; Wei WJ; Ma B; Lu ZW; Wang YL; Wang Y; Ji QH
    Int J Clin Exp Pathol; 2019; 12(1):267-274. PubMed ID: 31933742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
    Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
    Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.